摘要
目的观察岩黄连注射液联合肝动脉化疗栓塞术(TACE)治疗中晚期肝癌的临床疗效。方法将110例中晚期肝癌患者纳入研究范围,对照组(n=55)给予TACE治疗,治疗组(n=55)在TACE基础上辅助使用岩黄连注射液治疗。观察2组近期疗效、肿瘤标志物、肝功能、不良反应发生情况及无进展生存期、1年生存率、复发率。结果对照组有效率和疾病控制率分别为58.18%、72.73%;治疗组有效率和疾病控制率分别为83.64%、90.91%。2组近期疗效比较差异有统计学意义(P<0.05)。治疗前,2组CEA、AFP、CA199及ALT、AST、γ-GT、TBil比较差异无统计学意义(P>0.05)。治疗后,2组CEA、AFP、CA199及ALT、AST、γ-GT、TBil均明显低于治疗前(P<0.05),且治疗组CEA、AFP、CA199、ALT、AST、γ-GT、TBil低于对照组(P<0.05)。治疗组不良反应发生率为9.09%,与对照组(29.09%)比较,差异有统计学意义(P<0.05)。对照组和治疗组无进展生存期分别为(140.67±8.23)d、(171.43±12.42)d;1年生存率分别为70.91%、89.09%;复发率分别为43.64%、14.55%。治疗组无进展生存期明显长于对照组,1年生存率明显高于对照组,复发率明显低于对照组(P<0.05)。结论在TACE基础上辅助使用岩黄连注射液治疗中晚期肝癌具有良好的临床疗效,能够显著降低肿瘤标志物水平,促进肝功能恢复,且不良反应少。
Objective To investigate the therapeutic effects of Yanhuanglian injection combined with transcatheter arterial chemoembolization(TACE)on middle and advanced liver cancer.Methods A total of 110 patients with middle and advanced liver cancer were randomly divided into observation group(n=55)and control group(n=55).The patients in control group were treated with TACE whole those in treatment group were treated with Yanhuanglian injection combined with TACE.The short-term efficacy,the tumor marker level,liverfunction-related indexes,adverse effects,progression-free survival,one-year survival rate and recurrence rate were observed and compared between two groups.Results The effective rates and the disease control rates were 58.18%and 72.73%in control group and 83.64%and 90.91%in observation group,respectively(P<0.05).Before treatment,there were no significant differences in serum levels of CEA,AFP,CA199,ALT,AST,γ-GT and TBil between the two groups(P>0.05).After treatment,the serum levels of CEA,AFP,CA199,ALT,AST,γ-GT and TBil in both groups were significantly decreased(P<0.05),moreover,which in observation group were significantly lower than those in control group(P<0.05).In addition,the adverse effects rates were 29.09%and 9.09%in control group and observation group,respectively(P<0.05).The progression-free survival in observation group was(140.67±8.23)d,which was significantly longer than that(171.43±12.42)d in control group.Moreover the one-year survival rate in observation grou was 70.91%,which was significantly higher than that(89.09%)in control group,and the relapse rate(43.64%)in observation group was significantly higher than that(14.55%)in control group(P<0.05).Conclusion Yanhuanglian injection combined with TACE can significfantly reduce the tumor marker levels,promote the recovery of heptic function of patients with middle and advanced liver cancer,with less adverse effects.
作者
李淑荣
张芝华
葛锦泽
LI Shurong;ZHANG Zhihua;GE Jinze(Xuanhua Technology Occupation College,Hebei,Zhangjiakou 075100,China;不详)
出处
《河北医药》
CAS
2021年第12期1837-1840,共4页
Hebei Medical Journal
关键词
岩黄连注射液
中晚期
肝癌
化疗
Yanhuanglian injection
middle and advanced stage
liver cancer
chemotherapy
